25-26-24-1. “Board”
Sec. 1. As used in this chapter, “board” refers to the Indiana board of pharmacy. As added by P.L.51-2019, SEC.8.
25-26-24-10. “Patient”
Sec. 10. As used in this chapter, “patient” means an individual who has requested or received health care services from a provider for the examination, treatment, diagnosis, or prevention of a physical or mental condition. As added by P.L.51-2019, SEC.8.
25-26-24-11. “Practitioner”
Sec. 11. As used in this chapter, “practitioner” means a physician, dentist, veterinarian, podiatrist, nurse practitioner, scientific investigator, pharmacist, hospital, or other institution or individual licensed, registered, or otherwise permitted to distribute, dispense, conduct research with respect to, or administer a controlled substance in the course of professional practice or research in the United States. […]
25-26-24-12. “Prescription”
Sec. 12. As used in this chapter, “prescription” means an order for medication that is dispensed to or for a recipient. The term does not include an order for medication that is dispensed for immediate administration to the recipient. As added by P.L.51-2019, SEC.8.
25-26-24-13. “Pseudoephedrine”
Sec. 13. As used in this chapter, “pseudoephedrine” includes only pseudoephedrine that is dispensed pursuant to a prescription or drug order. As added by P.L.51-2019, SEC.8.
25-26-24-14. “Recipient”
Sec. 14. As used in this chapter, “recipient” means an individual for whom a controlled substance is dispensed. As added by P.L.51-2019, SEC.8.
25-26-24-15. “Recipient Representative”
Sec. 15. As used in this chapter, “recipient representative” means the individual to whom a controlled substance is dispensed if the recipient is either less than eighteen (18) years of age or unavailable to receive the controlled substance. As added by P.L.51-2019, SEC.8.
25-26-24-16. “State”
Sec. 16. As used in this chapter, “state” means any state of the United States or the District of Columbia. As added by P.L.51-2019, SEC.8.
25-26-24-17. Program Components; Recommendations; Retail Pharmacy
Sec. 17. (a) The board shall provide for an ephedrine, pseudoephedrine, and controlled substance prescription monitoring program that includes the following components: (1) Each time ephedrine, pseudoephedrine, or a controlled substance designated by the board under IC 35-48-2-5 through IC 35-48-2-10 is dispensed, the dispenser shall transmit to the INSPECT program the following information: (A) […]
25-26-24-18. Program Requirements; Execution of Contracts; Data; Funding
Sec. 18. (a) The INSPECT program must do the following: (1) Create a data base for information required to be transmitted under section 17 of this chapter in the form required under rules adopted by the board, including search capability for the following: (A) An ephedrine, pseudoephedrine, or a controlled substance recipient’s name. (B) An […]
25-26-24-19. Confidentiality; Disclosure; Release of Information; Applicants; Statistical Reports; Data Base; Immunity
Sec. 19. (a) Information received by the INSPECT program under section 17 of this chapter is confidential. (b) The board shall carry out a program to protect the confidentiality of the information described in subsection (a). The board may disclose the information to another person only under subsection (c), (d), or (g). (c) The board […]
25-26-24-19.5. Release of Inspect Information to a Veterinarian
Sec. 19.5. A practitioner who is a veterinarian and who is treating an animal may obtain information about: (1) the owner of the animal; or (2) the individual to whom an opioid or benzodiazepine will be dispensed for the animal; from the data base before prescribing an opioid or benzodiazepine for the animal. As added […]
25-26-24-2. “Committee”
Sec. 2. As used in this chapter, “committee” refers to the INSPECT oversight committee established by section 24 of this chapter. As added by P.L.51-2019, SEC.8.
25-26-24-2.5. “Controlled Substance”
Sec. 2.5. As used in this chapter, “controlled substance” has the meaning set forth in IC 35-48-1-9. The term includes gabapentin. As added by P.L.246-2019, SEC.21 and P.L.264-2019, SEC.10.
25-26-24-20. Certification Requirement
Sec. 20. A practitioner who is permitted to distribute, dispense, prescribe, conduct research with respect to, or administer ephedrine, pseudoephedrine, or a controlled substance in the course of the practitioner’s professional practice or research in the United States must be certified under section 19(d)(4) of this chapter to receive information from the INSPECT program. As […]
25-26-24-21. Review by Governing Board of Dissemination of Exception Reports; Investigation
Sec. 21. (a) Each board described in IC 25-0.5-11-1 that regulates a health care provider that prescribes or dispenses prescription drugs may review and act upon the unsolicited dissemination of exception reports under section 19 of this chapter. (b) Upon receipt of an exception report, the board may: (1) send the exception report to a […]
25-26-24-22. Rules; Standards; Intervention and Treatment
Sec. 22. (a) The board shall adopt rules under IC 4-22-2 to implement this chapter, including the following: (1) Information collection and retrieval procedures for the INSPECT program, including the controlled substances to be included in the program required under section 17 of this chapter. (2) Design for the creation of the data base required […]
25-26-24-23. Fund
Sec. 23. (a) The controlled substances data fund is established to fund the administration of the INSPECT program. The fund shall be administered by the Indiana professional licensing agency. (b) Expenses of administering the fund shall be paid from money in the fund. The fund consists of grants, public and private financial assistance, and the […]
25-26-24-24. Committee; Members; Recommendations; Meetings; Term
Sec. 24. (a) The INSPECT oversight committee is established. (b) The committee consists of the following members: (1) The president of the board or the president’s designee, who shall serve as the chairperson of the committee. (2) The commissioner of the state department of health or the commissioner’s designee. (3) The superintendent of the state […]
25-26-24-25. Violations
Sec. 25. A person who knowingly or intentionally releases confidential information in an unauthorized manner violates this chapter and commits a Class A misdemeanor. As added by P.L.51-2019, SEC.8.